Moderna succeeds in early stage human trial of COVID-19 Vaccine

19 May 2020, 8:53 am

More Good News from Moderna!

Moderna, Inc. a biotechnology company, today announced positive interim clinical data of a vaccine against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID).

At day 43, two weeks following the second dose, the levels of binding antibodies were at the levels seen in blood samples from people who have recovered from COVID-19. Moderna anticipates the dose for the Phase 3 study to be between 25 µg and 100 µg and expects Phase 3 trial initiation in July, subject to finalisation of the clinical trial protocol.


No Internet connection

Link Copied